Nautilus Biotechnology, Inc. — Director's Dealing 2021

Aug 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nautilus Biotechnology, Inc. (NAUT)
CIK: 0001808805
Period of Report: 2021-06-14

Reporting Person: Murphy Matthew B. (General Counsel)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-14	Stock Option (Right to Buy)	$10.1	A	326526	Acquired	2031-06-14	Common Stock (326526.0)	Direct

Footnotes

F1: Subject to the reporting person continuing to be a Service Provider (as defined in the Company's 2021 Equity Incentive Plan), 25% of the shares subject to such Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date (as defined below), and the balance of the shares subject to such Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary. The Vesting Commencement Date is April 1, 2021.